Atorvastatin decreases triacylglycerol-associated risk of vascular events in coronary heart disease patients

Lipids

Volumn 42, Issue 11, 2007, Pages 999-1009

  Athyros, Vasilios G ^a   Kakafika, Anna I ^a   Papageorgiou, Athanasios A ^a   Tziomalos, Konstantinos ^a   Skaperdas, Athanasios ^a   Pagourelias, Efstathios ^a   Pirpasopoulou, Athina ^a   Karagiannis, Asterios ^a   Mikhailidis, Dimitri P ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Coronary heart disease; Metabolic syndrome; Statins; Triacylglycerols; Vascular events

Indexed keywords

CORONARY HEART DISEASE; METABOLIC SYNDROME; TRIACYLGLYCEROLS; VASCULAR EVENTS;

BIOLOGICAL ORGANS; CARDIOVASCULAR SYSTEM; DISEASES; PATIENT MONITORING;

GLYCEROL;

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; DIABETES MELLITUS; DISEASE COURSE; DRUG DOSE TITRATION; DRUG EFFECT; FEMALE; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTIVARIATE ANALYSIS; RISK REDUCTION; STROKE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; UNIVARIATE ANALYSIS;

CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; FASTING; FEMALE; HEPTANOIC ACIDS; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PYRROLES; REGRESSION ANALYSIS; RISK FACTORS; TRIGLYCERIDES;

ANGINA;

EID: 36248963194     PISSN: 00244201     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11745-007-3103-z     Document Type: Article

References (43)

1. Castelli WP (1986) The triglyceride issue: a view from Framingham. Am Heart J 112:432-437
2. Assmann G, Schulte H (1992) Role of triglycerides in coronary artery disease: lessons from the Prospective Cardiovascular Munster Study. Am J Cardiol 70:10H-13H
3. Criqui MH, Heiss G, Cohn R, Cowan LD, Suchindran CM, Bangdiwala S, Kritchevsky S, Jacobs DR Jr, O'Grady HK, Davis CE (1993) Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med 328:1220-1225
4. Hokanson JE, Austin MA (1996) Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 3:213-219
5. Ninomiya JK, L'Italien G, Criqui MH, Whyte JL, Gamst A, Chen RS (2004) Association of the metabolic syndrome with history of myocardial infarction and stroke in the third national health and nutrition examination survey. Circulation 109:42-46
6. Sacks FM, for the Expert Group on HDL Cholesterol (2002) The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol 90:139-143
7. The UK HDL-C consensus group (2004) Role of fibrates in reducing coronary risk: a UK consensus. Curr Med Res Opin 20:241-247
8. Expert Panel on Detection, Evaluation, Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 285:2486-2497
9. Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, Mosca L, Pasternak RC, Pearson T, Pfeffer MA, Taubert KA (2006) AHA/ ACC guidelines for secondary prevention of patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung and Blood Institute. Circulation 113:2363-2372
10. British Cardiac Society., British Hypertension Society., Diabetes UK., HEART UK., Primary Care Cardiovascular Society., Stroke Association. (2005) JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 91(Suppl 5):v1-v52
11. Daskalopoulou SS, Mikhailidis DP (2006) Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe. Curr Med Res Opin 22:511-528
12. Athyros VG, Mikhailidis DP, Kakafika AI, Karagiannis A, Hatzitolios A, Tziomalos K, Ganotakis ES, Liberopoulos EN, Elisaf M (2007) Identifying and attaining LDL-C goals: mission accomplished? Next target: new therapeutic options to raise HDL-C levels. Curr Drug Targets 8:483-488
13. Athyros VG, Papageorgiou AA, Mercouris BR, Athyrou VV, Symeonidis AN, Basayannis EO, Demitriadis DS, Kontopoulos AG (2002) Treatment with atorvastatin to the National Cholesterol Educational Program goals versus usual care in secondary coronary heart disease prevention. The GREek Atorvastatin and coronary-heart-disease evaluation (GREACE) study. Curr Med Res Opin 18:220-228
14. Athyros VG, Mikhailidis DP, Papageorgiou AA, Bouloukos VI, Pehlivanidis AN, Symeonidis AN, Kakafika AI, Daskalopoulou SS, Elisaf M (2005) Effect of statins and aspirin alone and in combination on clinical outcome in dyslipidaemic patients with coronary heart disease. A subgroup analysis of the GREACE study. Platelets 16:65-71
15. Athyros VG, Mikhailidis DP, Papageorgiou AA, Symeonidis AN, Daskalopoulou SS, Kakafika AI, Pehlivanidis AN, Bouloukos VI, Langer A, GREACE Study Collaborative Group (2004) Relationship between LDL-C and non-HDL-C levels and clinical outcome in the GREek Atorvastatin and coronary-heart-disease evaluation (GREACE) study. Curr Med Ress Opin 20:1385-1392
16. Athyros VG, Mikhailidis DP, Papageorgiou AA, Bouloukos VI, Pehlivanidis AN, Symeonidis AN, Elisaf M, GREACE Study Collaborative Group (2004) Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease. J Hum Hypertens 18:781-788
17. Athyros VG, Mikhailidis DP, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI, Elisaf M (2004) The effect of statins versus untreated dyslipidemia on renal function in patients with coronary heart disease: a subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 57:728-734
18. Athyros VG, Elisaf M, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI, Milionis HJ, Mikhailidis DP, GREACE Study Collaborative Group (2004) Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and coronary-heart-disease evaluation (GREACE) study. Am J Kidney Dis 43:589-599
19. Liberopoulos EN, Mikhailidis DP, Athyros VG, Elisaf M (2006) The effect of cholesterol lowering treatment on renal function. Am J Kidney Dis 47:561
20. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Sperms JA, Costa F, American Heart Association, National Heart, Lung, Blood Institute (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/ National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112:2735-2752
21. Hopkins PN, Wu LL, Hunt SC, Brinton EA (2005) Plasma triglycerides and type III hyperlipidemia are independently associated with premature familial coronary artery disease. J Am Coll Cardiol 45:1003-1012
22. Stein EA, Lane M, Laskarzewski P (1998) Comparison of statins in hypertriglyceridemia. Am J Cardiol 81(4A):66B-69B
23. Ballantyne CM, Olsson AG, Cook TJ, Mercuri MF, Pedersen TR, Kjekshus J (2001) Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 104:3046-3051
24. Pyorala K, Ballantyne CM, Gumbiner B, Lee MW, Shah A, Davies MJ, Mitchel YB, Pedersen TR, Kjekshus J, Scandinavian Simvastatin Survival Study (4S) (2004) Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome. Subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 27:1735-1740
25. Girman CJ, Rhodes T, Mercuri M, Pyorala K, Kjekshus J, Pedersen TR, Beere PA, Gotto AM, Clearfield M, 4S Group, the AFCAPS/TexCAPS Research Group (2004) The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas coronary atherosclerosis prevention study (AFCAPS/TexCAPS). Am J Cardiol 93:136-141
26. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Manttari M, Heinonen OP, Frick MH (1992) Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki heart study. Implications for treatment. Circulation 85:37-45
27. Onat A, Sari I, Yazici M, Can G, Hergenc G, Avci GS (2006) Plasma triglycerides, an independent predictor of cardiovascular disease in men: a prospective study based on a population with prevalent metabolic syndrome. Int J Cardiol 108:89-95
28. Imke C, Rodriguez BL, Grove JS, McNamara JR, Waslien C, Katz AR, Willcox B, Yano K, Curb JD (2005) Are remnant-like particles independent predictors of coronary heart disease incidence? The Honolulu heart study. Arterioscler Thromb Vasc Biol 25:1718-1722
29. Kolovou GD, Anagnostopoulou KK, Daskalopoulou SS, Mikhailidis DP, Cokkinos DV (2005) Clinical relevance of postprandial lipaemia. Curr Med Chem 12:1931-1945
30. Athyros VG, Papageorgiou AA, Symeonidis AN, Elisaf M (2003) Non-high density lipoprotein cholesterol and coronary events during long-term statin treatment. Atherosclerosis 168:397-398
31. Stein DT, Devaraj S, Balis D, Adams-Huet B, Jialal I (2001) Effect of statin therapy on remnant lipoprotein cholesterol levels in patients with combined hyperlipidemia. Arterioscler Thromb Vasc Biol 21:2026-2031
32. Schaefer EJ, McNamara JR, Tayler T, Daly JA, Gleason JA, Seman LJ, Ferrari A, Rubenstein JJ (2002) Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary disease patients versus control subjects. Am J Cardiol 90:689-696
33. Schaefer EJ, McNamara JR, Tayler T, Daly JA, Gleason JL, Seman LJ, Ferrari A, Rubenstein JJ (2004) Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects. Am J Cardiol 93:31-39
34. Pontrelli L, Parris W, Adeli K, Cheung RC (2002) Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes. Metabolism 51:334-342
35. Guerin M, Lassel TS, Le Goff W, Farnier M, Chapman MJ (2000) Action of atorvastatin in combined hyperlipidemia: preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler Thromb Vasc Biol 20:189-197
36. Kontopoulos AG, Athyros VG, Papageorgiou AA, Hatzikon-standinou HA, Mayroudi MC, Boudoulas H (1996) Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease. Coron Artery Dis 7:843-850
37. Gazi IF, Tsimihodimos V, Tselepis AD, Elisaf M, Mikhailidis DP (2007) Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. Expert Opin Biol Ther 7:53-72
38. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J (1999) Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: veterans affairs high-density lipoprotein cholesterol intervention trial study group. N Engl J Med 341:410-418
39. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesaniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M, FIELD study investigators (2005) Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366:1849-1861
40. Athyros VG, Papageorgiou AA, Athyrou VV, Demitriadis DS, Kontopoulos AG (2002) Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care 25:1198-1202
41. Tsiara S, Elisaf M, Mikhailidis DP (2003) Early vascular benefits of statin therapy. Curr Med Res Opin 19:540-556
42. Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, Montori VM (2007) Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 49:403-414
43. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ, National Heart, Lung, Blood Institute; American College of Cardiology Foundation; American Heart Association (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110:227-239